From: healthline.com If your breast cancer has metastasized, or spread, it will be classified based on three receptors, like all invasive cancers are. Several treatments are available, but their effectiveness might vary based on your MBC subtype. Not all breast cancers are the same. If you’ve already received an MBC diagnosis, your doctor will likely perform additional tests. This information …
T-DXd Demonstrated Intracranial Activity in HER2+ Breast Cancer
By: Kristi Rosa From: oncnursingnews.com Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) led to promising and durable overall and intracranial activity in patients with HER2-positive metastatic breast cancer—regardless if they had stable or active brain metastases—according to data from the phase 3b/4 DESTINY-Breast12 study (NCT04739761) that were presented at the 2024 European Society for Medical Oncology (ESMO) Congress. In the cohort of patients …
Copper Depletion Combats Metastatic Recurrence in High-Risk TNBC
By: Ashling Wahner From: onclive.com Copper depletion with tetrathiomolybdate may decrease the risk of metastatic disease development in patients with triple-negative breast cancer (TNBC) at high risk of recurrence, according to Linda T. Vahdat, MD. In an interview with OncLive®, Vahdat discussed known factors regarding the role of copper in the development of tumor metastases, prior findings with the copper …
FDA Grants Fast Track Status to AC699 for ER+/HER2–, ESR1-Mutated Breast Cancer
By: Kristi Rosa From:.onclive.com The FDA has awarded fast track designation to the investigation of AC699 as a potential therapeutic option for patients with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated, advanced or metastatic breast cancer that progressed on or following 1 more lines of endocrine-based therapy.1 The orally bioavailable, chimeric ERα degrader is designed to bring an ER ligand to cereblon …
New ADC Results Mixed in Metastatic Breast Cancer
By :Jennie Smith From: medscape.com The landscape of antibody-drug conjugates, or ADCs, continues to grow more crowded in metastatic breast cancer. Indications are expanding, new agents are emerging, combinations with other drug classes are being tested, and many patients with this disease are now receiving more than one ADC. ADCs use antibodies to bind to the surface proteins of cancer …
Advancements in HER2-Directed Therapies Abound for HER2+ Metastatic Breast Cancer
By: Ashling Wahner From: onclive.com As the role of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) expands for patients with metastatic HER2-positive breast cancer and novel antibody-drug conjugates (ADCs) enter the scene, increasing familiarity with these agents can optimize treatment outcomes and minimize toxicities, according to Aditya Bardia, MD, MPH, FASCO. “It’s an exciting paradigm in terms of newer therapies that are coming …
Combination Therapy Shows Promise in Subset of Breast Cancers
By: Olivia Dimmer From: news.feinberg.northwestern.edu Combining two cancer drugs may be a promising treatment for advanced metastatic breast cancer, according to the results of a clinical trial published in the Journal of Clinical Oncology. Breast cancer is the most common cancer in women in the U.S., and roughly one in eight adult women will develop breast cancer in their lifetime, …
Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally
By: Chase Doyle From: ascopost.com A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized care and improved outcomes for patients diagnosed with this challenging disease. The staging system, developed by surgical oncologist Jennifer K. Plichta, MD, MS, of Duke University School of Medicine, stratifies patients …
Real-World Study Sheds Light on Treatment Sequences and Second-Line Outcomes in HER2+ Breast Cancer
By: Megan Hollasch From: onclive.com A real-world study published in the International Journal of Clinical Oncology demonstrated that most patients with HER2-positive metastatic breast cancer discontinued second-line treatment in US community practices, which study authors noted underscores the need for timely second-line treatment. Findings from the retrospective cohort revealed that at a median follow-up of 22 months (IQR, 13-37) from …
Dr Cobain on Future Considerations For the Treatment of HR+/HER2– Breast Cancer
By: Erin Cobain, MD From: onclive.com Erin Frances Cobain, MD, medical oncologist, co-director, Breast Cancer Clinical Research Team, Rogel Cancer Center, University of Michigan, discusses key takeaways derived from an OncLive Institutional Perspectives in Cancer webinar on breast cancer, highlighting patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. Investigators delved into a comprehensive array of topics surrounding breast cancer management, particularly …